Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

Novo Nordisk A/S, Apollo Global Management, and Blackstone are the three Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares in companies that are ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

Stan Wong, portfolio manager at Scotia Wealth Management, discusses his past stock picks and how they're doing in the market ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.

A produtora do Ozempic, Novo Nordisk, planeja fabricar mais medicamentos para o mercado dos Estados Unidos localmente; a ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Kepler Cheuvreux upgraded Novo Nordisk (NVO) to Buy from Hold with a price target of DKK 630, down from DKK 715. The firm views the company’s ...

The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...